Gujarat Themis Biosyn Ltd has approved the issuance of Non-Convertible Debentures (NCDs) worth up to ₹585 crore on a private placement basis. According to reports from CNBC TV18, the company's board approved the proposal at its meeting held on September 10, 2026. The proposed NCDs will not be listed on a stock exchange, with details of tenure, maturity date, coupon or interest rate, payment schedule for interest and principal, and any charge or security over assets to be disclosed in due course. The company disclosed this outcome in compliance with Regulation 30 and Regulation 51 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company demonstrated robust financial performance in the first quarter of FY27, achieving operational income of ₹43.79 crore, representing an increase from ₹35.87 crore in the first quarter of FY26. As reported by CNBC TV18, Gujarat Themis Biosyn experienced a 22% year-on-year rise in standalone net profit, reaching ₹11.07 crore for the June quarter. The profitability metrics showed significant improvement at the operational level, with EBITDA for Q1 FY27 reported at ₹20.79 crore, and the EBITDA margin increasing to 47.5% from 38.8% in the previous year.
Additional financial highlights for Q1 FY27 include profit before tax (PBT) of ₹15.17 crore and earnings per share (EPS) of ₹1.02 for the quarter, compared to ₹0.83 in Q1 FY26. According to CNBC TV18, the company's shares ended at ₹429.70, down by ₹1.60, or 0.37% on the BSE following the announcement. The company's historical stock performance shows +20.83% returns over one month and +51.63% returns over six months, demonstrating strong investor confidence despite the recent decline.
